Albany Molecular Research, Inc. (NASDAQ:AMRI) will announce its earnings results before the market opens on Wednesday, August 2nd. Analysts expect the company to announce earnings of $0.29 per share for the quarter. Albany Molecular Research has set its FY17 guidance at $1.08-1.20 EPS.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, May 9th. The biotechnology company reported $0.13 EPS for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.01. The company had revenue of $163.80 million for the quarter, compared to the consensus estimate of $161.43 million. Albany Molecular Research had a positive return on equity of 11.97% and a negative net margin of 11.26%. Albany Molecular Research’s quarterly revenue was up 55.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.07 earnings per share. On average, analysts expect Albany Molecular Research to post $1.13 EPS for the current fiscal year and $1.36 EPS for the next fiscal year.

Shares of Albany Molecular Research, Inc. (AMRI) opened at 21.69 on Wednesday. The stock’s market capitalization is $902.39 million. The firm’s 50-day moving average price is $21.62 and its 200-day moving average price is $17.72. Albany Molecular Research, Inc. has a 52-week low of $13.01 and a 52-week high of $22.17.

TRADEMARK VIOLATION NOTICE: “Albany Molecular Research, Inc. (NASDAQ:AMRI) to Release Quarterly Earnings on Wednesday” was posted by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/26/albany-molecular-research-inc-nasdaqamri-to-release-quarterly-earnings-on-wednesday.html.

A number of brokerages have issued reports on AMRI. First Analysis lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating in a research note on Monday, June 12th. J P Morgan Chase & Co lowered Albany Molecular Research from an “overweight” rating to a “neutral” rating in a research note on Thursday, June 8th. BidaskClub lowered Albany Molecular Research from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. William Blair lowered Albany Molecular Research from an “outperform” rating to a “market perform” rating in a research note on Tuesday, June 6th. Finally, Morgan Stanley lowered Albany Molecular Research from an “overweight” rating to an “equal weight” rating and set a $18.00 price target for the company. in a research note on Thursday, May 11th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating and four have given a hold rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $18.00.

Albany Molecular Research Company Profile

Albany Molecular Research, Inc is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Earnings History for Albany Molecular Research (NASDAQ:AMRI)

Receive News & Ratings for Albany Molecular Research Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc. and related companies with MarketBeat.com's FREE daily email newsletter.